(NKTR)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Nektar Therapeutics, biopharmaceutical kompaniyasi, Qo'shma Shtatlar va xalqaro miqyosda immunoterapiya sohasida dori-darmonlarni kashf qilish va ishlab chiqishga qaratilgan. U rezpegaldesleukinni ishlab chiqadi, bu autoimmun kasalliklar va yallig'lanish kasalliklari bilan og'rigan odamlarda asosiy immunitet tizimi muvozanatini davolash uchun 2b bosqichida; yarali kolit, vitiligo va ko'p sklerozni davolash uchun NKTR-0165; autoimmun kasalliklarni davolash uchun NKTR-0166; fibroz kasalliklarni davolash uchun NKTR-422; va qattiq o'smalar va katta B-hujayrali limfomani davolash uchun NKTR-255. U Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F bilan hamkorlik shartnomalariga ega. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; va Merck KGaA. Kompaniya 1990 yilda tashkil etilgan va shtab-kvartirasi San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jonathan Zalevsky Ph.D. | Senior VP and Chief Research & Development Officer |
| Dr. Ken Franke Ph.D. | Senior Vice President of Biologics Process Development & Manufacturing |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer |
| Mr. Howard W. Robin | CEO, President & Director |
| Mr. Jason Barnard | Chief Accounting Officer |
| Mr. Robert Bacci | Chief People Officer and Head of Quality & Facilities |
| Ms. Charleen Jue | Senior Vice President of Clinical Development Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-13 | 10-K | nktr-20251231.htm |
| 2026-03-12 | 8-K | ea0281334-8k_nektar.htm |
| 2026-01-27 | 8-K | ea0274309-8k_nektar.htm |
| 2025-12-16 | 8-K | d24251d8k.htm |
| 2025-11-21 | 8-K | ea0266707-8k_nektar.htm |
| 2025-11-10 | 8-K | ea0264736-8k_nektar.htm |
| 2025-11-07 | 10-Q | nktr-20250930.htm |
| 2025-11-06 | 8-K | ea0264261-8k_nektar.htm |
| 2025-09-18 | 8-K | ea0257842-8k_nektar.htm |
| 2025-08-08 | S-8 | ea0252127-s8_nektarthera.htm |
| Ms. Elizabeth Zhang | VP of Legal & Corporate Counsel |
| Ms. Jennifer Ruddock | Chief Business Officer |
| Ms. Sandra A. Gardiner | Interim Chief Financial Officer |